Vijoice
Vijoice ingredients
| Active ingredient | Strength |
|---|---|
| Alpelisib | 50 mg/1, 125 mg/1 |
What Vijoice is used for
The FDA lists the approved uses on the official label (below). In the EU, alpelisib is approved as Piqray for:
Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following an endocrine-based regimen (see section 5.1 and for biomarker-based patient selection see section 4.2).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Vijoice
- Generic name
- Alpelisib
- Made by
- Novartis Pharmaceuticals Corporation
- Forms
- Granule, Tablet
- Given
- Oral
- FDA approval
- New drug application (NDA) NDA218466
- On the US market since
- 2022
Official information
- MedlinePlus drug information (search for Alpelisib)
In India
- Alpelisib: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Vijoice?
Vijoice (Alpelisib) is a cancer medicine made by Novartis Pharmaceuticals Corporation, approved by the US FDA.
What are the ingredients of Vijoice?
Vijoice contains Alpelisib (50 mg/1, 125 mg/1).
Is Vijoice approved in Europe?
The same active substance is approved in the EU as Piqray, Vijoice.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA